Our purpose
Relieving manufacturing bottlenecks
Exothera is part of Univercells, a global life sciences leader with the mission of making biologics accessible to all
The Univercells Group has developed a reputation for creating rapidly scalable, affordable biologics production solutions that look to address enduring limitations within the biomanufacturing industry. Exothera was launched by Univercells in March 2020 as a contract development and manufacturing organization (CDMO) dedicated to supporting cell and gene therapy developers.
The company has been created to help tackle two of the most critical challenges manufacturers face in bringing these vital therapies to market – a lack of production capacity and scarcity of bioprocessing expertise, both of which keep costs unnecessarily high and slow the development and delivery of groundbreaking therapies from reaching those they can most help.
The aim is to dramatically reduce time and cost to market through an adaptable approach that enables the provision of scalable bioproduction processes to help cell and gene therapy innovators accelerate their delivery capabilities.
Exothera is part of Univercells, a global life sciences leader with the mission of making biologics accessible to all
The Univercells Group has developed a reputation for creating rapidly scalable, affordable biologics production solutions that look to address enduring limitations within the biomanufacturing industry. Exothera was launched by Univercells in March 2020 as a contract development and manufacturing organization (CDMO) dedicated to supporting cell and gene therapy developers.
The company has been created to help tackle two of the most critical challenges manufacturers face in bringing these vital therapies to market – a lack of production capacity and scarcity of bioprocessing expertise, both of which keep costs unnecessarily high and slow the development and delivery of groundbreaking therapies from reaching those they can most help.
The aim is to dramatically reduce time and cost to market through an adaptable approach that enables the provision of scalable bioproduction processes to help cell and gene therapy innovators accelerate their delivery capabilities.
Vision & Mission
Our ultimate goal at Exothera is to make life-changing therapies available for all. To achieve this, our teams’ mission is to design and deliver bespoke bioproduction journeys for innovators to achieve successful market entry for their viral vector or RNA therapeutics
Our philosophy
Exothera is your trusted CDMO partner who can help to rapidly and efficiently complete the process development and manufacture of just the right quantity of therapeutic to get through the next stage of clinical trials successfully, to secure further funding, and to move the therapy closer to market
Where we come from
Belgian and Walloon ecosystem
Launch of Univercells
Creation of Exothera to relieve viral vector manufacturing bottlenecks
With 15,000m² GMP capabilities Exothera is willing to relieve viral vector manufacturing bottlenecks.
The viral vector-based therapy market is expanding rapidly and Exothera will help to alleviate the three most critical challenges manufacturers face:
- Lack of expertise: there is a lack of C> specific expertise in this field; the CMC and manufacturing processes are highly specific.
- Capacity shortage: the number of specialized manufacturers is limited worldwide; manufacturing slot lead time of 12-18 months.
- High costs: cell & gene therapies are too expensive to be widely adopted; products priced between $85,000 and $2,100,000 for one patient!
Launch of nucleic acids services
Vision & Mission
Our ultimate goal at Exothera is to make life-changing therapies available for all. To achieve this, our teams’ mission is to design and deliver bespoke bioproduction journeys for innovators to achieve successful market entry for their viral vector or RNA therapeutics
Our philosophy
Exothera is your trusted CDMO partner who can help to rapidly and efficiently complete the process development and manufacture of just the right quantity of therapeutic to get through the next stage of clinical trials successfully, to secure further funding, and to move the therapy closer to market
Where we come from
Belgian and Walloon ecosystem
Launch of Univercells
Creation of Exothera to relieve viral vector manufacturing bottlenecks
With 15,000m² GMP capabilities Exothera is willing to relieve viral vector manufacturing bottlenecks.
The viral vector-based therapy market is expanding rapidly and Exothera will help to alleviate the three most critical challenges manufacturers face:
- Lack of expertise: there is a lack of C> specific expertise in this field; the CMC and manufacturing processes are highly specific.
- Capacity storage: the number of specialized manufacturers is limited worldwide; manufacturing slot lead time of 12-18 months.
- High costs: cell & gene therapies are too expensive to be widely adopted; products priced between $85,000 and $2,100,000 for one patient!